sanofi

Do you have *polymyalgia rheumatica (PMR)?*

Learn more about the EFC18055 ZIRCON Clinical study.

If you qualify and choose to participate, you'll be part of a clinical study that will evaluate the investigational study drug safety, how the study drug works, and how you tolerate the study drug.

To participate you must be:

- 50 years or older
- Newly diagnosed with polymyalgia rheumatica (PMR), and:
  - Haven't started treatment yet, OR
  - Have been taking prednisone (or similar corticosteroid) for 6 weeks or less at a dose of 30 mg/day or lower

OR

- Diagnosed within 1 year and recently relapsed (started taking medication and symptoms improved, but then got worse again)

Investigational Study Drug includes:

- 60% chance of Sarliumab injection every 2 weeks: 40% chance of placebo injection every 2 weeks.
- Daily prednisone taper throughout the study

Total length of study:

- Approximately 64 weeks

For more information or to find out if you qualify, contact:

Site Contact Name: **Donna Filippi, RN, CDDN**
Contact Information: **610-374-8133 ext. 1237**
Email: dfilippi@emkeyarthritis.com



Intended for U.S. Audiences Only © 2026 Sanofi US Services, Inc. All Rights Reserved.
The investigational study drug is approved by health authorities such as the US Food and Drug Administration (FDA) and is still under investigation for the treatment of PMR, so its effectiveness and safety have not been fully established.